• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

HHS secretary calls on drug companies to ‘stop the price hikes’

May 16, 2018 By Sarah Faulkner

capitol hillAfter President Donald Trump’s drug pricing speech last week was deemed a “non-event” by analysts, all eyes turned to the secretary of the U.S. Dept. of Health & Human Services, Alex Azar, to see what the former pharma executive viewed as the administration’s top concerns.

Azar called on the industry to “stop the price hikes” and cautioned that Trump would not hold back from calling out drug manufacturers by name – an effort echoed by FDA chief Dr. Scott Gottlieb who told STAT that the agency would publish the names of companies that are hindering generic drugs from reaching the market.

While Trump’s speech was light on the details, Azar dug into the administration’s priorities, focusing on their work regarding Medicare Part B and Part D plans.

On the campaign trail, Trump floated the idea of allowing Medicare to directly negotiate drug prices, arguing that the government is getting a bad deal on prices. But in his speech on Monday, Azar pointed to a study from the Congressional Budget Office that found that direct negotiation would “generate almost no savings.”

The HHS secretary said the president is instead interested in merging Medicare’s program for physician-administered drugs, Part B, with its program for prescription drugs, Part D. Under Medicare Part B, drugs that are cleared by the FDA are covered by Medicare without any negotiation.

“Medicare gets a bill for the drug, composed of the standard price plus a 6% markup and we pay it,” Azar said, according to his prepared remarks. “Compare that with the negotiation in Part D: Plans determine whether a drug should be covered or whether an alternative is superior. Plans negotiate discounts, rather than just paying full price.

“The President is also going to bring smart negotiation to billions of dollars’ worth of drugs in a part of Medicare where there is currently no negotiation at all,” Azar added.

Azar highlighted a number of other initiatives that Trump’s administration is considering, including eliminating “gag clauses” – rules that prevent pharmacists from telling patients if a cheaper drug is available to them – and re-examining the role of pharmacy benefit managers.

Azar, who formerly led Eli Lilly‘s (NYSE:LLY) U.S. division, struck an aggressive tone in addressing the industry, pointing towards his experience as an executive.

“I’ve been a drug company executive – I know the tired talking points: the idea that if one penny disappears from pharma profit margins, American innovation will grind to a halt,” he said. “I’m not interested in hearing those talking points anymore, and neither is the president.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Pharmaceuticals, Wall Street Beat Tagged With: Eli Lilly & Co.

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS